Item 7.01. Regulation FD Disclosure.

Penumbra, Inc. (the "Company") is scheduled to participate in a CEO Discussion with Bank of America on Tuesday, December 8, 2020 at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time. During that event, the Company anticipates providing updates and information about its vascular and neuro businesses across a range of topics. An analyst note was published on December 6, 2020, with an inaccurate estimate of the percentage of the Company's revenue for the fiscal quarter ended September 30, 2020 attributable to the Penumbra JET 7 Reperfusion Catheter with Xtra Flex technology ("JET 7 Xtra Flex"). JET 7 Xtra Flex represented 7.5% of the Company's total revenue for such quarter. Additional information will be discussed during Tuesday's event.

The information furnished on this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses